 |
Advanced particle engineering for increased dissolution and bioavailability of poorly soluble drugs, labile peptides and protein materials.
Enavail, LLC provides particle engineering expertise for increasing the bioavailability of poorly water-soluble drugs, and protein and peptide compounds.
Enavail’s core technologies are focused on two key areas:
- generating crystalline or amorphous forms of poorly water-soluble compounds, providing high potency and greatly enhanced dissolution and bioavailability and
- producing high surface area, non-degraded powder forms of labile proteins.
|
|
- Our proprietary particle design capabilities include novel, proven, and scalable technologies for use with multiple routes of administration (oral, pulmonary, intranasal, parenteral).
- A highly controllable “bottom up” approach is taken creating precise particle size and morphology.
- Enavail offers custom solutions to partners from initial drug screening (microgram to gram quantities) through to final product development.
- State of the art research and cGMP manufacturing facilities are located in Austin, Texas.
|
Management
Brian Windsor, Ph.D., President
 |
|
Brian Windsor serves as President of Enavail, LLC. For the past five years he has directed portfolio company management for Emergent Technologies, Inc. (ETI), an innovation management group and the management company of Enavail.
During his tenure at ETI, has served as Managing Director for ten of ETI’s portfolio companies and has served on ETI’s Strategic Planning Group, which assesses new technology opportunities and oversees formation and implementation of portfolio company strategy.
He holds a Ph.D. in molecular biology from the University of Texas at Austin and is a co-inventor on 15 patents.
Prior to joining ETI, Dr. Windsor served as founder and Vice President of Research and Development for Texagen, Inc., a startup biotech company. |
Robert O. "Bill" Williams III,
Ph.D., Chief Scientist
 |
Bill Williams is the Johnson & Johnson Centennial Professor of Pharmaceutics at the College of Pharmacy, University of Texas at Austin.
He earned a B.S. in Biology from Texas A&M University, a B.S. in Pharmacy from the University of Texas at Austin and Doctor of Philosophy in Pharmaceutics in 1986 from the University of Texas at Austin.
Dr. Williams worked 9 years in the pharmaceutical industry in the United States and France before returning to the University of Texas at Austin. Dr Williams was elected a Fellow of the American Association of Pharmaceutical Scientists in 2006 and a Fellow of the American Institute of Medical and Biological Engineering in 2008.
Dr. Williams is a member of the American Association of Colleges of Pharmacy, American Association of Pharmaceutical Scientists, American Chemical Society, Association de Pharmacie Galenique Industrielle, Controlled Release Society, and European Federation of Biotechnology.
|
He was the co-founder and President of PharmaForm LLC from 1996 to 2007, and is a Director of Akela Pharma, Inc. Dr. Williams’ research interests include development of novel drug delivery systems for oral, pulmonary, nasal, injectable, buccal and topical applications, development of novel particle engineering technologies for low molecular weight drugs, peptides and proteins, and analytical technologies to characterize actives, excipients and polymers. He has published over 225 articles, abstracts and book chapters in the fields of pharmaceutical technology and drug delivery.
In addition, Dr. Williams has co-edited one book. He is an inventor on numerous patents and patent applications.
|
Jason Vaughn,
Ph.D., Director of Research
 |
|
Jason Vaughn, Ph.D. serves as Director of Research for Emergent Technologies, Inc. (ETI) portfolio company Enavail, LLC.
Dr. Vaughn joined Emergent Technologies in April of 2011, and holds a Ph.D. in Pharmaceutics from The University of Texas at Austin.
During his thesis work under Robert O. Williams III, Dr. Vaughn co-developed seven patents in particle engineering for substance abuse deterrent delivery systems. His expertise extends to small particle technology to enhance dissolution rates and bioavailability, Particle engineering technologies and formulation development of nanoparticles for oral, pulmonary, nasal and buccal deliver, hot-melt extrusion as a method to formulate solid dispersions for controlled release and films for transmucosal, peptide and protein delivery, analytical characterization of peptides and proteins, and analytical method development, transfer, qualification and validation. |
Prior to joining Enavail, he worked as Director of Formulation Development for DPT Laboratories in San Antonio, TX, where he was responsible for the management of research and development activities to include preformulation, formulation development and packaging development. Managing a team of 30 personnel, he provided strategic, scientific and managerial leadership in the development of semisolids, liquids, pMDI and HME formulations from initial work through process validation.
Dr. Vaughn spent four years at PharmaForm LLC, Austin, TX, most recently as its Vice President of Operations responsible for the management of research and development activities and intellectual property for all non-inhalation PharmaForm owned platforms and products, a team of 60, and for the management of all contract based operations at PharmaForm including Manufacturing and Quality Control reporting to the Chief Operating Officer. |
|
|
